UBS Maintains Neutral on Xylem, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Positive 70.0%

Neg 0% Neu 0% Pos 70%

UBS analyst Joshua Spector maintains Xylem (NYSE:XYL) with a Neutral and raises the price target from $129 to $135.

Comments

No comments yet. Be the first!